Dr. Zandberg on Durvalumab Trial in Head and Neck Cancer

Name: Dr. Zandberg on Durvalumab Trial in Head and Neck Cancer
Uploaded: 2017-09-22T20:57:00.000Z
Description: Dan Zandberg, MD, assistant professor, medicine, University of Maryland School of Medicine, discusses the HAWK trial of durvalumab (Imfinzi) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

September 22, 2017

Dan Zandberg, MD

Video

Dan Zandberg, MD, assistant professor, medicine, University of Maryland School of Medicine, discusses the HAWK trial of durvalumab (Imfinzi) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

Overall response rate in this phase II trial was 16% with durable responses. Median overall survival was 7 months and a 1-year survival rate of 33%.

Additionally, patients who were HPV positive had a response rate higher than those who were HPV negative.